Autolus Therapeutics plc ADR (NASDAQ: AUTL) on Monday, plunged -4.80% from the previous trading day, before settling in for the closing price of $2.29. Within the past 52 weeks, AUTL’s price has moved between $2.20 and $7.45.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
A company in the Healthcare sector has jumped its sales by 190.29% annually for the last half of the decade. The company achieved an average annual earnings per share of 24.87%. With a float of $236.67 million, this company’s outstanding shares have now reached $266.12 million.
In an organization with 463 employees, it is important to assess its efficiency. In terms of profitability, gross margin is 51.97%, operating margin of -1739.83%, and the pretax margin is -2172.6%.
Autolus Therapeutics plc ADR (AUTL) Insider Updates
Observing investor behavior towards Biotechnology industry stocks is more important than anything else. The insider ownership of Autolus Therapeutics plc ADR is 11.06%, while institutional ownership is 56.28%. The most recent insider transaction that took place on Sep 16 ’24, was worth 2,955,674.
Autolus Therapeutics plc ADR (AUTL) Performance Highlights and Predictions
Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.22 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 24.87% per share during the next fiscal year.
Autolus Therapeutics plc ADR (NASDAQ: AUTL) Trading Performance Indicators
Autolus Therapeutics plc ADR (AUTL) is currently performing well based on its current performance indicators. A quick ratio of 13.64 was reported for the most recent quarter. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 57.50.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -1.21, a number that is poised to hit -0.21 in the next quarter and is forecasted to reach -0.78 in one year’s time.
Technical Analysis of Autolus Therapeutics plc ADR (AUTL)
Let’s dig in a bit further. During the last 5-days, its volume was 2.01 million. That was better than the volume of 1.5 million it reported in year-ago period. As of the previous 9 days, the stock’s Stochastic %D was 7.21%. Additionally, its Average True Range was 0.21.
During the past 100 days, Autolus Therapeutics plc ADR’s (AUTL) raw stochastic average was set at 0.70%, which indicates a significant decrease from 1.96% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 56.08% in the past 14 days, which was lower than the 71.94% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $3.39, while its 200-day Moving Average is $4.08. However, in the short run, Autolus Therapeutics plc ADR’s stock first resistance to watch stands at $2.30. Second resistance stands at $2.43. The third major resistance level sits at $2.50. If the price goes on to break the first support level at $2.11, it is likely to go to the next support level at $2.04. Assuming the price breaks the second support level, the third support level stands at $1.91.
Autolus Therapeutics plc ADR (NASDAQ: AUTL) Key Stats
Market capitalization of the company is 580.14 million based on 266,094K outstanding shares. Right now, sales total 1,700 K and income totals -208,380 K. The company made 0 K in profit during its latest quarter, and -58,270 K in sales during its previous quarter.
